Vr Adviser, LLC Viridian Therapeutics, Inc.\De Transaction History

Vr Adviser, LLC

$966 Million
Q3 2024

A detailed history of Vr Adviser, LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Vr Adviser, LLC holds 3,882,709 shares of VRDN stock, worth $76.8 Million. This represents 9.15% of its overall portfolio holdings.

Number of Shares

3,882,709

Previous 3,882,671 -0.0%

Holding current value

$76.8 Million

Previous $50.5 Million 74.87%

% of portfolio

9.15%

Previous 5.54%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$12.16 - $23.33 $462 - $886	38 Added 0.0%	3,882,709 $88.3 Million
Q1 2024 May 15, 2024	BUY	$17.09 - $23.82 $820 - $1,143	48 Added 0.0%	3,882,671 $68 Million
Q4 2023 Feb 14, 2024	BUY	$11.12 - $22.5 $8.9 Million - $18 Million	800,001 Added 25.95%	3,882,623 $84.6 Million
Q2 2023 Aug 11, 2023	BUY	$22.57 - $29.67 $8.64 Million - $11.4 Million	382,757 Added 14.18%	3,082,622 $73.3 Million
Q4 2022 May 15, 2023	BUY	$18.78 - $29.74 $10.7 Million - $16.9 Million	569,557 Added 26.74%	2,699,865 $78.9 Million
Q4 2022 Feb 14, 2023	BUY	$18.78 - $29.74 $10.7 Million - $16.9 Million	569,557 Added 26.74%	2,699,865 $78.9 Million
Q3 2022 May 15, 2023	BUY	$10.7 - $25.5 $2.97 Million - $7.07 Million	277,389 Added 14.97%	2,130,308 $43.7 Million
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $2.97 Million - $7.07 Million	277,389 Added 14.97%	2,130,308 $43.7 Million
Q2 2022 May 15, 2023	SELL	$9.55 - $19.0 $8.09 Million - $16.1 Million	-846,946 Reduced 31.37%	1,852,919 $21.4 Million
Q4 2021 Feb 14, 2022	BUY	$15.65 - $21.5 $28.7 Million - $39.4 Million	1,833,424 Added 9404.59%	1,852,919 $36.6 Million
Q4 2020 Feb 12, 2021	BUY	$7.28 - $21.0 $141,923 - $409,395	19,495 New	19,495 $321,000

Others Institutions Holding VRDN

# of Institutions

179

Shares Held

76.8M

Call Options Held

581K

Put Options Held

439K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $789M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vr Adviser, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vr Adviser, LLC with notifications on news.

Account